COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Other EventsItem 9.01.
|Item 9.01||Financial Statements and Exhibits.|
Story continues below
|99.1||Press release dated May3, 2018.|
Coherus BioSciences, Inc. ExhibitEX-99.1 2 d556654dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Coherus BioSciences Re-Submits Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate) REDWOOD CITY,…To view the full exhibit click
About COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS)
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs). COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Recent Trading Information
COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) closed its last trading session up +2.20 at 14.90 with shares trading hands.